Copper(II)-induced self-oligomerization of alpha-synuclein.
PDF (224K)
Journal: 1999/August - Biochemical Journal
ISSN: 0264-6021
PUBMED: 10359669
Abstract:
alpha-Synuclein is a component of the abnormal protein depositions in senile plaques and Lewy bodies of Alzheimer's disease (AD) and Parkinson's disease respectively. The protein was suggested to provide a possible nucleation centre for plaque formation in AD via selective interaction with amyloid beta/A4 protein (Abeta). We have shown previously that alpha-synuclein has experienced self-oligomerization when Abeta25-35 was present in an orientation-specific manner in the sequence. Here we examine this biochemically specific self-oligomerization with the use of various metals. Strikingly, copper(II) was the most effective metal ion affecting alpha-synuclein to form self-oligomers in the presence of coupling reagents such as dicyclohexylcarbodi-imide or N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline. The size distribution of the oligomers indicated that monomeric alpha-synuclein was oligomerized sequentially. The copper-induced oligomerization was shown to be suppressed as the acidic C-terminus of alpha-synuclein was truncated by treatment with endoproteinase Asp-N. In contrast, the Abeta25-35-induced oligomerizations of the intact and truncated forms of alpha-synuclein were not affected. This clearly indicated that the copper-induced oligomerization was dependent on the acidic C-terminal region and that its underlying biochemical mechanism was distinct from that of the Abeta25-35-induced oligomerization. Although the physiological or pathological relevance of the oligomerization remains currently elusive, the common outcome of alpha-synuclein on treatment with copper or Abeta25-35 might be useful in understanding neurodegenerative disorders in molecular terms. In addition, abnormal copper homoeostasis could be considered as one of the risk factors for the development of disorders such as AD or Parkinson's disease.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(60)
References
(47)
Diseases
(2)
Chemicals
(12)
Organisms
(1)
Processes
(6)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Biochem J 340(Pt 3): 821-828
PMID: 10359669

Copper(II)-induced self-oligomerization of alpha-synuclein.

Abstract

alpha-Synuclein is a component of the abnormal protein depositions in senile plaques and Lewy bodies of Alzheimer's disease (AD) and Parkinson's disease respectively. The protein was suggested to provide a possible nucleation centre for plaque formation in AD via selective interaction with amyloid beta/A4 protein (Abeta). We have shown previously that alpha-synuclein has experienced self-oligomerization when Abeta25-35 was present in an orientation-specific manner in the sequence. Here we examine this biochemically specific self-oligomerization with the use of various metals. Strikingly, copper(II) was the most effective metal ion affecting alpha-synuclein to form self-oligomers in the presence of coupling reagents such as dicyclohexylcarbodi-imide or N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline. The size distribution of the oligomers indicated that monomeric alpha-synuclein was oligomerized sequentially. The copper-induced oligomerization was shown to be suppressed as the acidic C-terminus of alpha-synuclein was truncated by treatment with endoproteinase Asp-N. In contrast, the Abeta25-35-induced oligomerizations of the intact and truncated forms of alpha-synuclein were not affected. This clearly indicated that the copper-induced oligomerization was dependent on the acidic C-terminal region and that its underlying biochemical mechanism was distinct from that of the Abeta25-35-induced oligomerization. Although the physiological or pathological relevance of the oligomerization remains currently elusive, the common outcome of alpha-synuclein on treatment with copper or Abeta25-35 might be useful in understanding neurodegenerative disorders in molecular terms. In addition, abnormal copper homoeostasis could be considered as one of the risk factors for the development of disorders such as AD or Parkinson's disease.

Full Text

The Full Text of this article is available as a PDF (224K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282–11286.[PMC free article] [PubMed] [Google Scholar]
  • Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995 Feb;14(2):467–475. [PubMed] [Google Scholar]
  • Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998 Apr;152(4):879–884.[PMC free article] [PubMed] [Google Scholar]
  • Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998 Jun;21(6):249–254. [PubMed] [Google Scholar]
  • Heintz N, Zoghbi H. alpha-Synuclein--a link between Parkinson and Alzheimer diseases? Nat Genet. 1997 Aug;16(4):325–327. [PubMed] [Google Scholar]
  • Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci. 1994;17:489–517. [PubMed] [Google Scholar]
  • Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994 May 23;345(1):27–32. [PubMed] [Google Scholar]
  • Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992 Sep 24;359(6393):322–325. [PubMed] [Google Scholar]
  • Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325–327. [PubMed] [Google Scholar]
  • Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992 Oct 2;258(5079):126–129. [PubMed] [Google Scholar]
  • Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2092–2096.[PMC free article] [PubMed] [Google Scholar]
  • Yoshimoto M, Iwai A, Kang D, Otero DA, Xia Y, Saitoh T. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9141–9145.[PMC free article] [PubMed] [Google Scholar]
  • Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27;276(5321):2045–2047. [PubMed] [Google Scholar]
  • Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998 Feb;18(2):106–108. [PubMed] [Google Scholar]
  • Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997 Aug 28;388(6645):839–840. [PubMed] [Google Scholar]
  • Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol. 1998 Feb;152(2):367–372.[PMC free article] [PubMed] [Google Scholar]
  • Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry. 1995 Aug 15;34(32):10139–10145. [PubMed] [Google Scholar]
  • Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res. 1991 Oct;11(3-4):335–343. [PubMed] [Google Scholar]
  • Uéda K, Saitoh T, Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1366–1372. [PubMed] [Google Scholar]
  • George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995 Aug;15(2):361–372. [PubMed] [Google Scholar]
  • Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT., Jr NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996 Oct 29;35(43):13709–13715. [PubMed] [Google Scholar]
  • Kim J. Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells. 1997 Feb 28;7(1):78–83. [PubMed] [Google Scholar]
  • Paik SR, Lee JH, Kim DH, Chang CS, Kim YS. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS Lett. 1998 Jan 2;421(1):73–76. [PubMed] [Google Scholar]
  • Askwith C, Kaplan J. Iron and copper transport in yeast and its relevance to human disease. Trends Biochem Sci. 1998 Apr;23(4):135–138. [PubMed] [Google Scholar]
  • Kaiser J. Alzheimer's: could there be a zinc link? Science. 1994 Sep 2;265(5177):1365–1365. [PubMed] [Google Scholar]
  • Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 1994 Sep 2;265(5177):1464–1467. [PubMed] [Google Scholar]
  • Fitzgerald DJ. Zinc and Alzheimer's disease. Science. 1995 Jun 30;268(5219):1920–1923. [PubMed] [Google Scholar]
  • Maggio JE, Esler WP, Stimson ER, Jennings JM, Ghilardi JR, Mantyh PW. Zinc and Alzheimer's disease. Science. 1995 Jun 30;268(5219):1920–1923. [PubMed] [Google Scholar]
  • Bush AI, Moir RD, Rosenkranz KM, Tanzi RE. Response. Science. 1995 Jun 30;268(5219):1921–1923. [PubMed] [Google Scholar]
  • Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9866–9868.[PMC free article] [PubMed] [Google Scholar]
  • Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I) Science. 1996 Mar 8;271(5254):1406–1409. [PubMed] [Google Scholar]
  • Paik SR, Lee JH, Kim DH, Chang CS, Kim J. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Arch Biochem Biophys. 1997 Aug 15;344(2):325–334. [PubMed] [Google Scholar]
  • Harrington CR. Dementia with Lewy bodies: the continuing enigma. Mol Med Today. 1996 Jan;2(1):4–6. [PubMed] [Google Scholar]
  • Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology. 1997 Mar;48(3):650–658. [PubMed] [Google Scholar]
  • Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF. The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci. 1995 Dec;134 (Suppl):69–78. [PubMed] [Google Scholar]
  • Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, LoIacono N, Cote L, Mayeux R. Altered systemic iron metabolism in Parkinson's disease. Neurology. 1997 Sep;49(3):714–717. [PubMed] [Google Scholar]
  • Morrissey JH. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981 Nov 1;117(2):307–310. [PubMed] [Google Scholar]
  • Penefsky HS. Reversible binding of Pi by beef heart mitochondrial adenosine triphosphatase. J Biol Chem. 1977 May 10;252(9):2891–2899. [PubMed] [Google Scholar]
  • Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. [PubMed] [Google Scholar]
  • Lee JH, Shin HJ, Chang CS, Paik SR. Comparisons of the NACP self-oligomerizations induced by Abeta25-35 in the presence of dicyclohexylcarbodiimide and N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline. Neurochem Res. 1998 Nov;23(11):1427–1434. [PubMed] [Google Scholar]
  • Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J. 1997 Apr 15;323(Pt 2):539–546.[PMC free article] [PubMed] [Google Scholar]
  • Harper JD, Lansbury PT., Jr Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385–407. [PubMed] [Google Scholar]
  • Regan L. Protein design: novel metal-binding sites. Trends Biochem Sci. 1995 Jul;20(7):280–285. [PubMed] [Google Scholar]
  • Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, et al. The cellular prion protein binds copper in vivo. Nature. 1997 Dec 18;390(6661):684–687. [PubMed] [Google Scholar]
  • Huang EP. Metal ions and synaptic transmission: think zinc. Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13386–13387.[PMC free article] [PubMed] [Google Scholar]
  • Choi DW, Koh JY. Zinc and brain injury. Annu Rev Neurosci. 1998;21:347–375. [PubMed] [Google Scholar]
  • Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469–6473.[PMC free article] [PubMed] [Google Scholar]
Department of Biochemistry, College of Medicine, Inha University, 253 Yonghyun-Dong, Nam-Ku, Inchon 402-751, Korea. srpaik@dragon.inha.ac.kr
Department of Biochemistry, College of Medicine, Inha University, 253 Yonghyun-Dong, Nam-Ku, Inchon 402-751, Korea. srpaik@dragon.inha.ac.kr
Copyright notice

Abstract

alpha-Synuclein is a component of the abnormal protein depositions in senile plaques and Lewy bodies of Alzheimer's disease (AD) and Parkinson's disease respectively. The protein was suggested to provide a possible nucleation centre for plaque formation in AD via selective interaction with amyloid beta/A4 protein (Abeta). We have shown previously that alpha-synuclein has experienced self-oligomerization when Abeta25-35 was present in an orientation-specific manner in the sequence. Here we examine this biochemically specific self-oligomerization with the use of various metals. Strikingly, copper(II) was the most effective metal ion affecting alpha-synuclein to form self-oligomers in the presence of coupling reagents such as dicyclohexylcarbodi-imide or N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline. The size distribution of the oligomers indicated that monomeric alpha-synuclein was oligomerized sequentially. The copper-induced oligomerization was shown to be suppressed as the acidic C-terminus of alpha-synuclein was truncated by treatment with endoproteinase Asp-N. In contrast, the Abeta25-35-induced oligomerizations of the intact and truncated forms of alpha-synuclein were not affected. This clearly indicated that the copper-induced oligomerization was dependent on the acidic C-terminal region and that its underlying biochemical mechanism was distinct from that of the Abeta25-35-induced oligomerization. Although the physiological or pathological relevance of the oligomerization remains currently elusive, the common outcome of alpha-synuclein on treatment with copper or Abeta25-35 might be useful in understanding neurodegenerative disorders in molecular terms. In addition, abnormal copper homoeostasis could be considered as one of the risk factors for the development of disorders such as AD or Parkinson's disease.

Abstract
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.